Overview

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.
Phase:
Phase 2
Details
Lead Sponsor:
Center for International Blood and Marrow Transplant Research
Collaborators:
Genzyme, a Sanofi Company
Sanofi
Treatments:
JM 3100
Plerixafor